Nuvation Bio Inc.
NUVB- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001811063
No open-market purchases or sales by Nuvation Bio Inc. insiders were filed in the last 90 days; 259 institutions reported holding it in 13F filings for Q3 2026, worth $1.40B in total; 3 superinvestors hold it, including Duquesne Family Office and Abrams Capital.
Key figures
- Market capClose on Nov 20, 2026
- $1.34B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +19 vs. previous quarter
- 259
- 13F valueReported value at the end of Q3 2026
- $1.40B
- Superinvestors holdingAt the end of Q3 2026
- 3
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $62.9M
- +699.0% year over year
- Net income, FY2025
- -$204.6M
- No comparable prior period
- Free cash flow, FY2025
- -$181.4M
- No comparable prior period
- Revenue, Q3 FY2026
- $45.0M
- +242.6% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $204.6M (325.3% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 62.0M
- Shares sold short
- Change
- −1.22M
- −1.9% vs. previous
- Days to cover
- 12.50
- At average daily volume
Superinvestors holding NUVB, Q3 2026
Go to the superinvestors tab3 superinvestors report holding Nuvation Bio Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
0.3%
Nuvation Bio Inc.'s share of the portfolio
- Shares
- 2,269,900
- Value
- $12.7M
| Superinvestor | Weight | Value |
|---|---|---|
| Greenlight Capital | <0.1% | $196.0K |
Latest insider trades
See all insider tradesOpen-market purchases and sales by Nuvation Bio Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 21, 2026 (view filing)4:49 PM ET | Aug 19 | 2 days | Hattersley GaryCHIEF SCIENTIFIC OFFICER | SSaleClass A Common Stock | −100.0K | $7.09 | −$709.2K | −100.0%0 after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 23 | 1 day | Sauvage PhilippeChief Financial Officer | SSaleClass A Common Stock | −47.7K | $6.01 | −$286.5K | −79.0%12.7K after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 23 | 1 day | Markel StacyCHIEF PEOPLE OFFICER | SSaleClass A Common Stock | −125.0K | $6.03 | −$753.8K | −79.3%32.6K after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 23 | 1 day | Wentworth KerryCHIEF REGULATORY OFFICER | SSaleClass A Common Stock | −63.0K | $6.02 | −$379.3K | −54.3%53.0K after | 10b5-1 |
| Jun 11, 2026 (view filing) | Jun 9 | 2 days | Mashal RobertDirector | PPurchaseClass A Common Stock | +25.0K | $4.73 | +$118.3K | +12.5%225.0K after | |
| Apr 21, 2026 (view filing) | Apr 17 | 4 days | Liu DongfangCHIEF MEDICAL OFFICER | SSaleClass A Common Stock | −50.0K | $5.02 | −$251.0K | −73.5%18.0K after | 10b5-1 |
| Apr 21, 2026 (view filing) | Apr 17 | 4 days | Wentworth KerryCHIEF REGULATORY OFFICER | SSaleClass A Common Stock | −36.8K | $5.01 | −$184.1K | −40.9%53.0K after | 10b5-1 |
| Apr 8, 2026 (view filing) | Apr 6 | 2 days | Wentworth KerryCHIEF REGULATORY OFFICER | SSaleClass A Common Stock | −200.0K | $4.52 | −$904.0K | −79.1%53.0K after | 10b5-1 |
| Dec 3, 2025 (view filing) | Dec 1 | 2 days | Liu DongfangCHIEF MEDICAL OFFICER | SSaleClass A Common Stock | −150.0K | $7.82 | −$1.17M | −89.3%18.0K after | |
| Nov 26, 2025 (view filing) | Nov 25-26 | 1 day | Liu DongfangCHIEF MEDICAL OFFICER | SSaleClass A Common Stock | −20.0K | $7.75 | −$155.0K | −52.6%18.0K after | 2 lots |
Top 10 13F holders, Q3 2026
See all 259 holdersThe largest institutional positions in Nuvation Bio Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 52,668,484 | $294.9M | 0.01% | +438,189+0.8% | Added |
| BlackRock, Inc. | 28,924,444 | $162.0M | 0.00% | +1,293,607+4.7% | Added |
| Decheng Capital LLC | 25,954,439 | $145.3M | 21.22% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 12,152,903 | $68.1M | 0.00% | +233,389+2.0% | Added |
| Laurion Capital Management LP | 7,697,272 | $43.1M | 3.26% | −122,741−1.6% | Reduced |
| State Street Corp | 7,596,209 | $42.5M | 0.00% | +225,415+3.1% | Added |
| Omega Fund Management, LLC | 7,151,031 | $40.0M | 31.99% | −930,058−11.5% | Reduced |
| Geode Capital Management, LLC | 6,446,677 | $36.1M | 0.00% | +201,872+3.2% | Added |
| American Century Companies Inc | 4,519,041 | $25.3M | 0.01% | +19,398+0.4% | Added |
| Goldman Sachs Group Inc | 4,511,958 | $25.3M | 0.00% | +2,607,272+136.9% | Added |
Holders of 5% or more of NUVB
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Nuvation Bio Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 15.00%50.6M shares | +1.50 ppfrom 13.50% | May 10, 20218 filings | May 12, 2025 | SEC |
| BlackRock, Inc. | 13G | 6.40%21.7M shares | +1.50 ppfrom 4.90% | Apr 28, 20252 filings | Jul 17, 2025 | SEC |